Search

Your search keyword '"Bürger Katharina"' showing total 321 results

Search Constraints

Start Over You searched for: Author "Bürger Katharina" Remove constraint Author: "Bürger Katharina"
321 results on '"Bürger Katharina"'

Search Results

1. Performance evaluation of automated white matter hyperintensity segmentation algorithms in a multicenter cohort on cognitive impairment and dementia

2. Aggregation-resistant alpha-synuclein tetramers are reduced in the blood of Parkinson’s patients

3. Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS

4. Fornix fractional anisotropy mediates the association between Mediterranean diet adherence and memory four years later in older adults without dementia

5. Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: Evaluation in Alzheimer's disease

6. Distinct molecular profiles of skull bone marrow in health and neurological disorders

7. Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome

8. Linking early-life bilingualism and cognitive advantage in older adulthood

9. Lifelong experiences as a proxy of cognitive reserve moderate the association between connectivity and cognition in Alzheimer's disease

10. Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies.

11. Investigating biological age as a predictor of symptom progression in Alzheimer’s disease

12. Blood‐based quantification of Aβ oligomers indicates impaired clearance from brain in ApoE ε4 positive subjects

13. Longitudinal changes of self‐ and informant‐reported cognitive decline in elderly with regard to clinical progression and amyloid‐status

14. Contributions of enlarged perivascular spaces and white matter hyperintensities to cognitive performance in the Alzheimer’s disease continuum – shared and unique effects

15. Longitudinal morphometry of medial temporal lobe subregions in earlyAlzheimer’s disease

16. Minor neuropsychological deficits in SCD: Association with AD biomarkers and cognitive decline

17. Biomarker interplay between CSF p‐tau and 18F‐PI‐2620 PET in Alzheimer’s disease and 4R‐tauopathy

18. Altered BOLD Signal Fluctuations in precuneus relate to inflammatory markers and vascular risk in the AD spectrum

19. Memorability of photographs in subjective cognitive decline and mild cognitive impairment: Implications for cognitive assessment

20. Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease—Data from three memory clinic studies

21. 17 Biomarker interplay between CSF p-tau and18F-PI-2620 PET in Alzheimer’s disease and 4R-tauopathy

22. CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume

23. Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

27. 9 .Nicht-medikamentöse Therapie

28. Subcortical tau‐accumulation predicts neuronal dysfunction in the cortex based on functional connectivity in 4R‐tauopathies

29. Two progression patterns in Alzheimer's disease identified from structural MRI in a memory clinic‐based cohort

30. Speed of cognitive decline in biomarker stratified SCD subgroups

31. Biomarker interplay between CSF p‐tau and 18F‐PI‐2620 PET in Alzheimer's disease and 4R‐tauopathy.

32. Levels of astrocyte‐derived glial fibrillary acidic protein (GFAP) and S100 calcium‐binding protein B (S100B) in the cerebrospinal fluid within the early stages of Alzheimer´s Disease.

34. Current cave monitoring practices, their variation and recommendations for future improvement in Europe: A synopsis from the 6th EuroSpeleo Protection Symposium

35. Supplementary material 1 from: Weigand AM, Bücs S-L, Deleva S, Lukić Bilela L, Nyssen P, Paragamian K, Ssymank A, Weigand H, Zakšek V, Zagmajster M, Balázs G, Barjadze S, Bürger K, Burn W, Cailhol D, Decrolière A, Didonna F, Doli A, Drazina T, Dreybrodt J, Ðud L, Egri C, Erhard M, Finžgar S, Fröhlich D, Gartrell G, Gazaryan S, Georges M, Godeau J-F, Grunewald R, Gunn J, Hajenga J, Hofmann P, Knight LRFD, Köble H, Kuharic N, Lüthi C, Munteanu CM, Novak R, Ozols D, Petkovic M, Stoch F, Vogel B, Vukovic I, Hall Weberg M, Zaenker C, Zaenker S, Feit U, Thies J-C (2022) Current cave monitoring practices, their variation and recommendations for future improvement in Europe: A synopsis from the 6th EuroSpeleo Protection Symposium. Research Ideas and Outcomes 8: e85859. https://doi.org/10.3897/rio.8.e85859

36. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

37. Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease.

40. Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers

41. Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer’s disease

42. Relevance of Subjective Cognitive Decline in Older Adults with a First-Degree Family History of Alzheimer's Disease

44. Additive value of [18F]PI-2620 perfusion imaging in four-repeat tauopathies

45. Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency

46. Cost of illness of apathy in Alzheimer’s disease

47. A microRNA signature that correlates with cognition and is a target against cognitive decline

50. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

Catalog

Books, media, physical & digital resources